

**Cardioplegia in paediatric cardiac surgery: a systematic review of randomised controlled trials**

Nigel E Drury <sup>1,2</sup>, Ivan Yim <sup>1</sup>, Akshay J Patel <sup>1</sup>, Nicola K Oswald <sup>1</sup>, Cher-Rin Chong <sup>3</sup>, John Stickley <sup>1</sup>, Timothy J Jones <sup>1</sup>

<sup>1</sup> Department of Paediatric Cardiac Surgery, Birmingham Children's Hospital, Birmingham, UK

<sup>2</sup> Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK

<sup>3</sup> Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK

Word count: 4999

PROSPERO registration: CRD42017080205

Correspondence: Mr Nigel Drury, Department of Paediatric Cardiac Surgery, Birmingham Children's Hospital, Steelhouse Lane, Birmingham, B4 6NH, UK

tel: +441213338731, fax: +441213339441, email: [n.e.drury@bham.ac.uk](mailto:n.e.drury@bham.ac.uk)

22    **Visual abstract**

23    *Key question:* What is the randomised controlled trial evidence for different cardioplegia  
24    strategies in paediatric cardiac surgery?

25    *Key findings:* 26 small, single-centre trials identified. Heterogeneity of patients, interventions  
26    & outcomes prohibited meta-analysis.

27    *Take-home message:* There are no late phase clinical trials of cardioplegia in children; high-  
28    quality, multi-centre trials should be conducted to improve care.

29

30    *Central image:* PRISMA flow diagram of study selection.

31

## Abstract

*Objectives:* Cardioplegia is the primary method for myocardial protection during cardiac surgery. We conducted a systematic review of randomised controlled trials of cardioplegia in children to evaluate the current evidence-base.

*Methods:* We searched MEDLINE, CENTRAL and LILACS, and manually screened retrieved references and systematic reviews to identify all randomised controlled trials comparing cardioplegia solutions or additives in children undergoing cardiac surgery published in any language; secondary publications and those reporting inseparable adult data were excluded. Two or more reviewers independently screened studies for eligibility and extracted data; the Cochrane Risk of Bias tool was used to assess for potential biases.

*Results:* We identified 26 trials randomising 1,596 children undergoing surgery; all were single centre, phase II trials, recruiting few patients (median 48, IQR 30-99). The most frequent comparison was blood versus crystalloid in 10 (38.5%) trials and the most common endpoints were biomarkers of myocardial injury (17, 65.4%), inotrope requirements (15, 57.7%) and length of stay in intensive care (11, 42.3%). However, the heterogeneity of patients, interventions and reported outcome measures prohibited meta-analysis. Overall risk of bias was high in 3 (11.5%), unclear in 23 (88.5%) and low in none.

*Conclusions:* The current literature on cardioplegia in children contains no late phase trials. The small size, inconsistent use of endpoints and low quality of reported trials provides a limited evidence-base to inform practice. A core outcome set of clinically important, standardised, validated endpoints for assessing myocardial protection in children should be developed to facilitate the conduct of high-quality, multi-centre trials.

*PROSPERO registration:* CRD42017080205

*Key words:* systematic review, clinical trials, cardioplegia, myocardial protection, paediatric cardiac surgery

## Introduction

The use of cardioplegia has been fundamental to the intracardiac repair of congenital heart lesions for over 40 years. In conjunction with hypothermia, it remains the primary method for myocardial protection against ischemia-reperfusion injury during cardiac surgery, inducing electromechanical arrest to allow access to a still and bloodless field. Cardioplegic arrest reduces myocardial oxygen uptake to only 10% of the perfused beating heart, and progressive hypothermia leads to a further stepwise reduction [1]. However, myocardial damage still occurs routinely following ischemia-reperfusion, as demonstrated by the universal release of troponin [2]. Ventricular dysfunction may follow repair of even the simplest lesions [3], manifesting as low cardiac output and requiring inotropic support in the early postoperative period. The immature myocardium exhibits marked differences from the adult heart, including substrate metabolism, calcium handling, insulin sensitivity and antioxidant defence against free radicals [4]. Current cardioplegia techniques are primarily derived from adult or laboratory models and may not be optimal for young children, especially neonates and those with preoperative cyanosis [5-7].

Recent surveys of practice have shown marked variations in the use of commercially-available and customised cardioplegia solutions in children in North America [8] and worldwide [9]. The composition, dilution, dose, temperature, route of administration and time interval between doses varied between surgeons and continents, but few surgeons adjusted their technique according to the age of the patient [8]. These findings suggest that the choice of solution is determined primarily by the individual surgeon, institution or country rather than the physiology of the patient, and that this may be due to a lack of evidence to support one technique over another. We therefore conducted a systematic review of all randomised controlled trials (RCTs) of cardioplegia in paediatric cardiac surgery to evaluate the value and quality of the current evidence-base.

## Methods

This review was conducted with reference to the Cochrane handbook for systematic reviews of interventions [10,11] and reported in accordance with the PRISMA statement [12]. All eligibility criteria, search terms and data items were prespecified and the review was prospectively registered on PROSPERO (CRD42017080205) (<https://www.crd.york.ac.uk/PROSPERO>).

### *Trial eligibility*

All randomised and quasi-randomised clinical trials comparing cardioplegia solutions or additives in children undergoing cardiac surgery published in any language were included. The definition of a child was based upon the authors' characterization and cardioplegia was defined as a solution injected into the cardiac vasculature during surgery with the aim of causing electromechanical arrest.

Trials were excluded if the outcome measures were not related to the use of cardioplegia for myocardial protection. Those including both adults and children were only included if the publication presented the paediatric data separately. Secondary publications, sub-studies or long-term outcomes of previously reported trials were excluded unless the results were specifically related to cardioplegia when the original report was not. Trials published only as a conference abstract or for which all options to obtain the full text publication were exhausted, were excluded due to insufficient data for analysis.

### *Search strategy*

We searched international primary research databases (MEDLINE, CENTRAL, LILACS) from inception to October 31, 2017 and reference lists of relevant articles, systematic

reviews and meta-analyses to identify all eligible studies. We combined previously validated search strategies to identify randomised controlled trials, studies including children and those using cardioplegia as an investigational medicinal product (see supplemental material for detailed search terms). For example, to identify RCTs in MEDLINE, we used the Cochrane Highly Sensitive Search Strategy for identifying randomised trials: sensitivity- and precision-maximizing version [10] and to identify studies including children, we adapted the improved Cochrane Childhood Cancer Group filter for PubMed developed by Leclercq and colleagues [13].

#### *Study selection and data extraction*

Abstracts and then full text publications of all identified articles were screened independently by two reviewers (IY and NED) to generate a database of included studies. Data were extracted independently by two reviewers (two of IY, AJP, NKO, C-RC and NED) from the full trial publication and any published protocols or supplemental material; any assessments of trials in previous systematic reviews were corroborated. A full list of data items, descriptors is available in the supplemental material. Any disagreements on study selection or data extraction were resolved by consensus. Non-English language articles were evaluated in conjunction with individuals with a clinical or research methodology background and fluent in that language (C-RC for Chinese, see acknowledgements).

#### *Risk of bias assessment*

The Cochrane Risk of Bias Tool was used to define the risk of bias for each of the included trials according to the following domains: sequence generation, allocation concealment, blinding of participants, personnel and outcome assessors, incomplete outcome data, selective outcome reporting and other potential threats to validity [11]. Trials were rated as

low risk, unclear or high risk of bias for each factor; overall risk of bias was determined for each trial as low (low risk in all domains), high (high risk of bias in one or more domains) or unclear (neither of the above).

#### *Statistical analysis*

Statistical analysis was performed using *R* (<https://www.r-project.org/>). All continuous data were expressed as medians with interquartile ranges (IQR) and categorical data as counts and percentages where relevant. Pearson correlation was used to assess the relationship between the number of children randomised per trial and the year of publication.

The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

## Results

From 132 unique records, we identified 26 RCTs published to October 31, 2017, randomising 1,596 children undergoing surgery with cardioplegic arrest, of whom 1549 (97.1%) were included in analysis of the primary endpoint. The flow of studies through the systematic review process is documented in figure 1. All full text articles were sourced online, via national libraries or directly from the authors; references of included trials are listed in the supplementary material.

Characteristics of the included trials are shown in table 1. All studies were single centre, phase II trials, originating from 11 countries, with China (9, 34.6%), Japan (4, 15.4%) and Turkey (3, 11.5%) being the most frequent and only one (3.8%) from the United States. Eight (30.7%) trials were published in a language other than English: 7 (26.9%) in Chinese and one (3.8%) in Turkish. Trials were most commonly published in specialist cardiothoracic surgery journals (14, 53.8%) with none reaching high-impact cardiovascular or general medical journals.

The number of children randomised ranged between 20 and 138 with a median of 48 (IQR 30-99). Only 4 (15.4%) trials analysed fifty or more patients per arm and the median duration of recruitment was 12 months (IQR 6-16.5). The median age of patients was 29.5 months (IQR 18.2-54.0) and just 21 (1.4%) neonates (confirmed or probable) were included; no trial specifically assessed the use of cardioplegia in neonates. There was no significant correlation between the number of patients recruited per trial and the year of publication ( $R = 0.19$ ). Most surgical procedures were low risk with 255 (16.4%) children undergoing operations with a Risk Adjusted classification for Congenital Heart Surgery (RACHS-1) score of 3 or above [14] and the mean aortic cross-clamp time across studies was 60 minutes. The most frequent comparison was blood versus crystalloid cardioplegia in 10 (38.5%) trials followed by various additives in 6 (23.1%) trials (table 1).



## *Outcome measures*

Thirteen trials (50.0%) had a defined primary endpoint, one of which (cardiac index) was a clinical outcome; none reported mortality as the primary endpoint. The most common outcome measures were biomarkers of myocardial injury (17, 65.4%), inotrope requirements (15, 57.7%) and length of stay in intensive care (11, 42.3%) (table 2). However, there was marked heterogeneity within endpoints relating to the metrics of assessment used (table 3).

Serum biomarker assays of myocardial injury were: cardiac troponin (cTn) in 13 (50.0%), specifically the cTn-I subunit in 11 (42.3%) and cTn-T subunit in 3 (11.5%); serum creatine kinase MB isoenzyme (CK-MB) in 8 (30.8%); and heart-type fatty acid binding protein (h-FABP) in 2 (7.7%). These measures were inconsistently reported as concentrations at timepoints from reperfusion to 48 hours, peak value, total release/activity, and area under the time-concentration curve (AUC); scheduling of sample collection was variable and timed from reperfusion, end of CPB, end of surgery or arrival on ICU. Similarly, inotrope use was reported as binary need for support, dose at the end of surgery or postoperative intervals, maximal dose, total dose in the first 24 hours, duration of use and various inotrope scores over differing time periods. The heterogeneity of patients, interventions and reported outcome measures thereby prohibited meta-analysis. Only short-term outcomes up to discharge or 30 days were reported.

## *Quality of trials*

Regarding standards for the conduct and reporting of clinical trials, [15] 4 (15.4%) performed a sample size calculation, 2 (7.7%) were prospectively registered on a publicly-accessible trial database, and 2 (7.7%) published a CONSORT flow diagram. None of the 26 trials were overseen by an independent Data Monitoring Committee and none were stopped early or extended.

194 Risk of bias assessment for each of the eight domains and overall is shown in figure 2.  
195 Overall risk of bias was high in 3 (11.5%) trials, unclear in 23 (88.5%) and low in none; the  
196 high proportion of unclear resulted from poor reporting of randomisation and masking  
197 procedures, and an inability to exclude selective reporting due to a lack of trial registration or  
198 published protocol.

199

## Discussion

RCTs represent the gold standard in evaluating healthcare interventions through rigorous testing of a predefined protocol and minimization of bias [15]. Yet in this systematic review of the published literature, we identified only 26 RCTs of cardioplegia in paediatric cardiac surgery; these were exclusively single centre, phase II trials that were rarely prospectively registered, recruited small numbers of patients, lacked independent oversight and were not reported to international standards [15-16]. Furthermore, the heterogeneity of patients, interventions and reported outcome measures across trials precluded the pooling of results for meta-analysis. Of concern is the finding that studies included few neonates, in whom myocardial metabolism and cellular homeostasis differ from the more mature heart and the effects of cardioplegia are less well understood [4]. As a result, these trials provide a limited evidence-base to support clinical decision-making on cardioplegia, a technique which is so fundamental to the surgical management of children with congenital heart disease. Whilst all cardioplegia solutions are efficacious in arresting the heart, differences in their effectiveness to reduce ischaemia-reperfusion injury and therefore improve outcomes, are unknown.

Our findings reflect those of a previous, more limited meta-analysis of cardioplegia trials in children. Fang et al compared the efficacy of blood versus crystalloid cardioplegia and identified 5 RCTs published in English prior to mid-2013, recruiting 358 children in total [17]. They found no difference in cTn-I release at 4-6, 12 or 24 hours (3 trials), duration of ventilation (3 trials) or length of ICU stay (4 trials). Only blood lactate following CPB (4 trials) was significantly lower in the blood cardioplegia group but this difference was prejudiced by one study, without which there was no effect. Inotrope use was reported in all 5 trials, but the reviewers were unable to pool data due to the diverse metrics used. Risk of bias was assessed using the modified Jadad scale, a flawed method of quality assessment, with all trials classified as 'high quality' despite only one scoring >5 on the 8-point scale. They

concluded that there was no evidence of improvement in myocardial injury or clinical outcomes but were limited by the small number of patients and variability in age, preoperative cyanosis and techniques used. Similarly, Mylonas et al recently identified many non-randomised or retrospective studies on paediatric cardioplegia but few RCTs [18], a finding that is commonplace throughout the global paediatric cardiac surgery literature. In a recent systematic review of RCTs published since 2000, we identified few late-phase clinical trials; most were small, single-centre studies of low value, uncertain quality and at risk of systematic bias [19]. This lack of evidence to guide clinical practice fosters uncertainty and predisposes to variability in patient care.

Low cardiac output syndrome following surgery is the commonest premonitory complication in children and the most frequent seminal event leading to death [20]. The ubiquitous release of troponin following aortic cross-clamping in children demonstrates that myocardial injury occurs *routinely* and is therefore not a problem solved [2,4]. Myocardial protection remains an area of active research; 18% of recent clinical trials in paediatric cardiac surgery evaluated cardioplegia, ischemic conditioning or other drugs to reduce myocardial injury [19]. However, the wide range of variables in cardioplegia technique has led to a potpourri of studies evaluating different aspects of practice. Of the papers identified in this review, blood versus crystalloid cardioplegia was the most common comparison (10, 38.5%) but was often combined with other differences between groups, such as warm versus cold or autologous versus allogenic blood, making direct comparison between studies more difficult and limiting meta-analysis. This variability in the techniques evaluated by clinical trials reflects the current state of clinical practice; the second most commonly used formulations of cardioplegia for children in North America are customised solutions (34%) unique to each centre [8], essentially a ‘none of the above’ homebrew, emphasizing the lack of evidence for an optimal cardioplegia solution. As such the widespread adherence to local solutions may also provide a barrier to conducting multi-centre clinical trials.

253

254 To facilitate the synthesis of findings from multiple studies, clinical trials must report valid  
255 and comparable outcome measures. We found marked variation in the reporting of  
256 endpoints between trials with inconsistent use of metrics to evaluate the same outcome  
257 (table 3). Biomarkers of myocardial injury were the most commonly used outcome measure  
258 but included one or more of serum troponin-I, troponin-T, CK-MB and h-FABP, measured at  
259 varying timepoints up to 48 hours, and variably reported as measured concentrations, peak  
260 or AUC. This disparity reflects the absence of a standardized method for reporting biomarker  
261 release after ischemia-reperfusion in children as it is unknown which metric has greatest  
262 discriminatory power. Following coronary surgery in adults, cumulative AUC troponin at 72  
263 hours has been shown to best predict mid-term mortality [21]. However, obtaining blood  
264 samples even up to 48 hours is more problematic in children, especially with expedited  
265 removal of venous lines during an uneventful recovery [22]. Newer measures of myocardial  
266 injury, such as h-FABP and high-sensitivity troponin, may have an earlier peak and greater  
267 positive predictive value [23-25] but currently lack validation in this cohort [26]. Other  
268 outcome measures also differed in their definition, timing and measurement. Inotropic  
269 support in the early postoperative period was reported using various metrics of dose,  
270 duration or a combination through an inotrope score; recently, maximum vasoactive-inotropic  
271 score has been identified as the optimal measure of pharmacologic cardiovascular support  
272 after cardiac surgery in infants and is strongly associated with morbidity and mortality [27].  
273 Length of stay on ICU was usually recorded as actual time elapsed rather than assessed  
274 against objective criteria such as fitness for discharge. Furthermore, all trials reported only  
275 short-term endpoints with no functional or long-term outcomes.

276

277 Heterogeneity of outcome measures is a common problem in systematic reviews and limits  
278 the ability to conduct meta-analyses of pooled data. The Core Outcome Measures in

Effectiveness Trials (COMET) initiative is an international effort to develop core outcome sets for clinical trials, defined as ‘the minimum that should be measured and reported in all clinical trials of a specific condition’ [28]. Yet there are currently no core outcome sets relevant to any aspect of children’s heart surgery registered on the COMET database. Endpoints such as vasoactive inotrope score [27] and duration of postoperative mechanical ventilation [29] have been validated in large datasets and should form the basis of such an endeavour. A set of standardized, evidence-based endpoints would have enabled selection of the same metrics across trials, reduced the risk of outcome reporting bias, and increased the value of individual studies by facilitating evidence synthesis. To approve new drugs, the FDA looks for endpoints that are clinically meaningful and ideally measure directly how a patient ‘feels, functions or survives’ [30]; however, none of the trials reported outcomes beyond discharge or 30 days and there is little evidence to correlate perioperative variables to the long-term functional outcomes that are most important to patients, such as exercise tolerance and quality of life.

The strengths of this systematic review include the comprehensive search strategy, independent review procedures and obtainment of the full text of all potential articles in all languages. The limitations include: a risk of reporting bias, although unpublished studies would be expected to be of lower value; an inability to perform any meta-analyses to inform clinical practice due to the paucity of comparable studies; and limiting the scope to RCTs, which are not the only source of valuable evidence to inform clinical practice.

## *Conclusions*

This comprehensive systematic review demonstrates that the current literature on cardioplegia in children contains no late phase trials. The small size, inconsistent use of endpoints and low quality of reported trials provides a limited evidence-base to inform clinical

practice; neonates were particularly poorly represented. This lack of evidence combined with marked variations in care [8,9] demonstrates clinical equipoise and the need for high-quality, late phase, multi-centre clinical trials to determine which of the current cardioplegic solutions provide the best myocardial protection for defined patient groups. An agreed core outcome set of clinically important, standardized, validated endpoints for assessing myocardial protection in children should be developed to facilitate the conduct of such trials and the meta-analysis of pooled data. Improving our understanding of how these perioperative endpoints relate to long-term functional outcomes will be key to improving myocardial protection, especially in those who have cumulative exposure to ischemia-reperfusion through multiple operations.

**Acknowledgements:** We are most grateful to Angela Reed and Stuart Purchase in the Library at Birmingham Children's Hospital for locating many of the articles. We thank Dr. Safak Alpat, Stollery Children's Hospital, Edmonton, Canada for translation from Turkish.

**Funding:** Nigel Drury is funded by an Intermediate Clinical Research Fellowship from the British Heart Foundation (FS/15/49/31612). The authors received no specific funding for this study.

**Conflict of interest:** none declared.



326 **Figure legends**

327

328 **Figure 1.** PRISMA flow diagram of study selection.

329 RCT, randomised controlled trial. \* includes multiple counting.

330

331 **Figure 2.** Cochrane Risk of bias scores for included trials.

332

**Table 1.** Characteristics of included trials.

Characteristic	n (%)	Characteristic	n (%)
Phase II, single-centre	26 (100%)	Design	
Country of origin		Parallel groups	25 (96.2%)
China	9 (34.6%)	Factorial	1 (3.8%)
Japan	4 (15.4%)	Randomisation	
Turkey	3 (11.5%)	Simple unrestricted	11 (42.3%)
Iran	2 (7.7%)	Block/stratified	1 (3.8%)
United Kingdom	2 (7.7%)	Unclear	14 (53.8%)
Belgium	1 (3.8%)	Intervention comparisons	
India	1 (3.8%)	Blood v crystalloid *	10 (38.5%)
Italy	1 (3.8%)	Additives	6 (23.1%)
Serbia	1 (3.8%)	Herbal additive	3 (11.5%)
Sweden	1 (3.8%)	Non-herbal additive	3 (11.5%)
United States	1 (3.8%)	Warm terminal dose (hot shot) *	3 (11.5%)
Language of publication		Autologous v allogenic blood *	2 (7.7%)
English	18 (69.2%)	Custodiol HTK v St. Thomas'	2 (7.7%)
Chinese	7 (26.9%)	del Nido v St. Thomas'	2 (7.7%)
Turkish	1 (3.8%)	Warm v cold *	2 (7.7%)
Number of arms		Celsior v St. Thomas'	1 (3.8%)
Two	20 (76.9%)	Leukocyte depletion	1 (3.8%)
Three	6 (23.1%)	Potassium concentration	1 (3.8%)

\* includes multiple counting. HTK: Histidine-Tryptophan-Ketoglutarate.

**Table 2.** Defined outcome measures most frequently reported in included trials.

Outcome measure	n (%)
Clinical	
Inotrope requirements	15 (57.7%)
Length of stay in ICU	11 (42.3%)
Duration of mechanical ventilation	10 (38.5%)
Length of stay in hospital	7 (26.9%)
Cardiac output/index	4 (15.9%)
LV function on echocardiography	4 (15.9%)
Non-clinical	
Biomarkers of myocardial injury	17 (65.4%)
Arterial lactate	8 (30.8%)
Myocardial biopsy histology	5 (19.2%)
Myocardial biopsy ATP	4 (15.9%)
Biomarkers of systemic inflammation	4 (15.9%)
Coronary sinus lactate	3 (11.5%)

ATP: adenosine triphosphate; ICU: intensive care unit; LV: left ventricle.

343 **Table 3.** Outcome metrics for serum biomarkers and inotropes reported in included trials.

344

Authors	Year	Biomarkers of myocardial injury	Inotropes
Matsuda H et al	1989	CK-MB: peak *	-
Mori F et al	1990	CK-MB: 1, 3, 6, 12, 24, 48 h, total release/activity *	Use
Young JN et al	1997	-	Inotrope score, total dose 8 h
Hayashi Y et al	2000	CK-MB: peak (6, 12, 18, 24 h) h-FABP: 50 min	Peak dose
Caputo M et al	2002	cTnI: AUC 48 h (4, 12, 24, 48 h)	Use, duration
Toyoda Y et al	2003	cTnT: reperfusion, 1, 3, 6, 18 h h-FABP: reperfusion, 1, 2, 3 h	-
Han HG et al	2004	-	-
Modi P et al	2004	cTnI: AUC 48 h (1, 4, 12, 24, 48 h)	Duration, total dose
Amark K et al	2006	-	Total dose 24 h
Cuccurullo L et al	2006	-	-
Deng YK et al	2006	CK-MB: end op, 6, 12, 24, 48 h cTnI: end op, 6, 12, 24, 48 h cTnT: end op, 6, 12, 24, 48 h	-
Deng YK et al	2007	-	-
Jin ZX et al	2008	cTnI: 1, 3, 6, 12, 24 h	Duration, inotrope score: 1, 3, 6, 12, 24, 48 h
Deng YK et al	2009	-	-
Duvan I et al	2009	CK-MB: reperfusion, 4, 12, 24, 48 h cTnT: reperfusion, 4, 12, 24, 48 h	Use, duration
Zhang Q et al	2009	-	Use
Poncelet AJ et al	2011	cTnI: reperfusion, 6, 12, 24 h	Use
Liu Y et al	2012	cTnI: 1, 3, 6, 12, 24 h *	Inotrope score: 1, 3, 6, 12, 24, 48 h
Cheng GC et al	2013	CK: 30 min, 24 h	-
Korun O et al	2013	-	-

Ma C et al	2013	CK-MB: end CPB cTnl: end CPB	Use
Nezafati MH et al	2013	-	-
Kuşlu S et al	2015	CK-MB: end op, 4, 16, 24, 48 h cTnl: end op, 4, 16, 24, 48 h *	Peak dose, dose: end op, 4, 8, 12, 16, 20, 24, 48 h
Mimic B et al	2016	cTnl: reperfusion, 1, 4, 12, 24 h *	Level 24 h, duration
Gorjipour F et al	2017	cTnl: reperfusion, 24 h	-
Talwar S et al	2017	cTnl: end CPB, 24 h	VIS: 1, 2, 3, 4 d

---

\* indicates defined primary outcome. AUC: area under the curve; CK: creatine kinase; CK-MB: creatine kinase MB isoenzyme; CPB: cardiopulmonary bypass; cTnl: cardiac troponin I subunit; cTnT: cardiac troponin T subunit; h-FABP: heart-type fatty acid binding protein; VIS: vasoactive inotrope score.

## References

- 1 Buckberg GD, Brazier JR, Nelson RL, Goldstein SM, McConnell DH, Cooper N. Studies of the effects of hypothermia on regional myocardial blood flow and metabolism during cardiopulmonary bypass. I. The adequately perfused beating, fibrillating and arrested heart. *J Thorac Cardiovasc Surg* 1977;73:87-94.
- 2 Mildh LH, Pettilä V, Sairanen HI, Rautiainen PH. Cardiac troponin T levels for risk stratification in pediatric open heart surgery. *Ann Thorac Surg* 2006;82:1643-9.
- 3 Chaturvedi RR, Lincoln C, Gothard JW, Scallan MH, White PA, Redington AN, et al. Left ventricular dysfunction after open repair of simple congenital heart defects in infants and children: quantification with the use of a conductance catheter immediately after bypass. *J Thorac Cardiovasc Surg* 1998;115:77-83.
- 4 Doenst T, Schlensak C, Beyersdorf F. Cardioplegia in pediatric cardiac surgery: do we believe in magic? *Ann Thorac Surg* 2003;75:1668-77.
- 5 del Nido PJ, Mickle DA, Wilson GJ, Benson LN, Weisel RD, Coles JG, et al. Inadequate myocardial protection with cold cardioplegia arrest during repair of tetralogy of Fallot. *J Thorac Cardiovasc Surg* 1988;95:223-9.
- 6 Imura H, Caputo M, Parry A, Pawade A, Angelini GD, Suleiman MS. Age-dependent and hypoxia-related differences in myocardial protection during paediatric open heart surgery. *Circulation* 2001;103:1551-6.
- 7 Najm HK, Wallen WJ, Belanger MP, Williams WG, Coles JG, Van Arsdel GS, et al. Does the degree of cyanosis affect myocardial adenosine triphosphate levels and function in children undergoing surgical procedures for congenital heart disease? *J Thorac Cardiovasc Surg* 2000;119:515-24.

- 375 8 Kotani Y, Tweddell J, Gruber P, Pizarro C, Austin EH 3<sup>rd</sup>, Woods RK, et al. Current  
376 cardioplegia practice in pediatric cardiac surgery: a North American multiinstitutional  
377 survey. *Ann Thorac Surg* 2013;96:923-9.
- 378 9 Harvey B, Shann KG, Fitzgerald D, Mejak B, Likosky DS, Puis L, et al. International  
379 pediatric perfusion practice: 2011 survey details. *J Extra Corpor Technol* 2012;44:186-  
380 93.
- 381 10 Lefebvre C, Manheimer E, Glanville J. Searching for Studies. In: Higgins JPT, Green S,  
382 eds. *Cochrane Handbook for Systematic Reviews of Interventions*. Chichester: Wiley,  
383 2011. [www.handbook.cochrane.org](http://www.handbook.cochrane.org) [accessed February 21, 2017]
- 384 11 Higgins JPT, Altman DG, Sterne JAC. Assessing risk of bias in included studies. In:  
385 Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of*  
386 *Interventions*. Chichester: Wiley, 2011. [www.handbook.cochrane.org](http://www.handbook.cochrane.org) [accessed  
387 February 21, 2017]
- 388 12 Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic  
389 reviews and meta-analyses: the PRISMA statement. *Br Med J* 2009;339:b2535.
- 390 13 Leclercq E, Leeflang MM, van Dalen EC, Kremer LC. Validation of search filters for  
391 identifying pediatric studies in PubMed. *J Pediatr* 2013;162:629-34.
- 392 14 Jenkins KJ, Gauvreau K, Newburger JW, Spray TL, Moller JH, Iezzoni LI. Consensus-  
393 based method for risk adjustment for surgery for congenital heart disease. *J Thorac*  
394 *Cardiovasc Surg* 2002;123:110-8.
- 395 15 Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for  
396 reporting parallel group randomised trials. *Br Med J* 2010;340:c332.

- 397 16 Hartling L, Wittmeier KDM, Caldwell P, van der Lee H, Klassen TP, Craig JC *et al.* StaR  
398 Child Health: Developing evidence-based guidance for the design, conduct, and  
399 reporting of pediatric trials. *Pediatrics* 2012;129:S112-7.
- 400 17 Fang Y, Long C, Lou S, Guan Y, Fu Z. Blood versus crystalloid cardioplegia for pediatric  
401 cardiac surgery: a meta-analysis. *Perfusion* 2015;30:529-36.
- 402 18 Mylonas KS, Tzani A, Metaxas P, Schizas D, Boikou V, Economopoulos KP. Blood  
403 versus crystalloid cardioplegia in pediatric cardiac surgery: a systematic review and  
404 meta-analysis. *Pediatr Cardiol* 2017;38:1527-39.
- 405 19 Drury NE, Patel AJ, Oswald NK, Chong C-R, Stickley J, Barron DJ, *et al.* Randomised  
406 controlled trials in children's heart surgery in the 21<sup>st</sup> century: a systematic review. *Eur J*  
407 *Cardiothorac Surg* 2017 [in press]. doi:10.1093/ejcts/ezx388.
- 408 20 Gaies M, Pasquali SK, Donohue JE, Dimick JB, Limbach S, Burnham N, *et al.* Seminal  
409 postoperative complications and mode of death after pediatric cardiac surgical  
410 procedures. *Ann Thorac Surg* 2016;102:628-35.
- 411 21 Ranasinghe AM, Quinn DW, Richardson M, Freemantle N, Graham TR, Mascaro J, *et*  
412 *al.* Which troponometric best predicts midterm outcome after coronary artery bypass  
413 graft surgery? *Ann Thorac Surg* 2011;91:1860-7.
- 414 22 Modi P, Suleiman MS, Reeves B, Pawade A, Parry AJ, Angelini GD, Caputo M.  
415 Myocardial metabolic changes during pediatric cardiac surgery: a randomized study of 3  
416 cardioplegic techniques. *J Thorac Cardiovasc Surg* 2004;128:67-75.
- 417 23 Hasegawa T, Yoshimura N, Oka S, Ootaki Y, Toyoda Y, Yamaguchi M. Evaluation of  
418 heart fatty acid-binding protein as a rapid indicator for assessment of myocardial  
419 damage in pediatric cardiac surgery. *J Thorac Cardiovasc Surg* 2004;127:1697-1702.



- 24 Ağırbaşı M, Nguyen ML, Win K, Kunselman AR, Clark JB, Myers JL, et al. Inflammatory and hemostatic response to cardiopulmonary bypass in pediatric population: feasibility of seriological testing of multiple biomarkers. *Artif Organs* 2010;34:987-95.
- 25 Westermann D, Neumann JT, Sörensen NA, Blankenberg S. High-sensitivity assays for troponin in patients with cardiac disease. *Nat Rev Cardiol* 2017;14:472-83.
- 26 Evers ES, Walavalkar V, Pujar S, Balasubramanian L, Prinzen FW, Delhaas T, et al. Does heart-type fatty acid binding protein predict clinical outcomes after pediatric cardiac surgery? *Ann Pediatr Cardiol* 2017;10:245-7.
- 27 Gaies MG, Jeffries HE, Niebler RA, Pasquali SK, Donohue JE, Yu S, et al. Vasoactive-inotropic score is associated with outcome after infant cardiac surgery: an analysis from the Pediatric Cardiac Critical Care Consortium and Virtual PICU system registries. *Pediatr Crit Care Med* 2014;15:529-37.
- 28 Core Outcome Measures in Effectiveness Trials initiative. <http://www.comet-initiative.org> [accessed February 21, 2017]
- 29 Gaies M, Werho DK, Zhang W, Donohue JE, Tabbutt S, Ghanayem NS et al. Duration of postoperative mechanical ventilation as a quality metric for pediatric cardiac surgical programs. *Ann Thorac Surg* 2018;105:615-21.
- 30 Temple RJ. A regulatory authority's opinion about surrogate endpoints. In: Nimmo WS, Tucker GT, eds. *Clinical measurement in drug evaluation*. New York: John Wiley & Sons; 1995: 3-22.